...
XOMAPSMALL

XOMA Corporation

HealthcareBiotechnology
$25.77
$0.00(-1.10%)
52W$24.96
$30.00
FinancialsValuationvs RPRX
Updated Mar 5, 12:00 AM
RSI38
RS Rating41/99
Beta0.13
Volatility13%
F-Score4/9
Mkt Cap$317M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

XOMA Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 41), showing significant lag compared to the market leaders. Earnings growth of 144% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.

Relative Strength
41
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.13
vs S&P 500
LOW VOL
52W Position
16%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$26.26
50 SMA > 100 SMA$26.38
100 SMA > 150 SMA$26.30
150 SMA > 200 SMA$26.15

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$25.97-0.76%BELOW
50 SMA$26.26-1.87%BELOW
100 SMA$26.38-2.31%BELOW
150 SMA$26.30-2.02%BELOW
200 SMA$26.15-1.46%BELOW

Price Performance

1D-1.1%
1W-0.4%
1M-0.9%
3M-2.8%
6M-3.7%
YTD-4.9%
1Y+0.4%
3Y+1.0%
52-Week Trading Range16% from low
$25.77
52W Low$24.96
52W High$30.00

Technical Indicators

RSI (14)BEARISH
38.3
305070
VCP ScoreCOOL
5/10
Base depth: 5.3%

Risk Profile

Beta
0.13
52W Vol
13%
ATR
$0.16
Max DD (1Y)
-5%

Volume Analysis

Today
20
50D Avg
991
Vol Ratio
0.02x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+144%
$0.82
Q1'25+107%
$0.06
Q2'25-48%
$0.52
Q3'25+144%
$0.70
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+4.21%
5 Years:+9.17%
3 Years:-9.28%
TTM:+118.02%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+163.25%

Stock Price CAGR

10 Years:+0.54%
5 Years:+0.56%
3 Years:+1.04%
1 Year:+0.39%

Return on Equity

10Y Avg:-568.1%
5Y Avg:-6.6%
3Y Avg:-22.5%
Last Year:20.1%

Key Metrics

Market Cap$317M
Gross Margin99.3%
Net Margin-48.5%
Piotroski F-Score4/9

More XOMAP Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

XOMAP vs RPRXRPRXLGNDINVABTX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 41 meansXOMAP outperformed 41% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.13 means 87% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is XOMAP in an uptrend right now?

XOMAP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is XOMAP overbought or oversold?

XOMAP's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.

Is XOMAP outperforming the market?

XOMAP has a Relative Strength (RS) Rating of 41 out of 99. XOMAP is currently lagging the broader market.

Where is XOMAP in its 52-week range?

XOMAP is trading at $25.77, which is 86% of its 52-week high ($30.00) and 16% above its 52-week low ($24.96).

How volatile is XOMAP?

XOMAP has a Beta of 0.13 and 52-week volatility of 13%. It's less volatile than the S&P 500 - generally more stable.